What are the most valuable longevity startups?

Top startups in the longevity market ranked by valuation

Here is an updated table that ranks the top startups in the longevity market based on their latest reported or estimated valuations.

If you need to dig deeper and get more detailed data, please check our report covering the longevity market.

1. Total funding: capital committed by investors at launch (January 2022), not necessarily all paid in.
2. Total funding includes the primary proceeds of its IPO.

Which longevity startup is worth the most right now?

Oura is the most valuable longevity startup in our ranking, at $11.0B, followed by WHOOP at $10.1B.

Our ranking covers 147 longevity startups, and the top positions belong to products people can use today. Oura sells a smart ring and a paid health membership. WHOOP has built its business around a screenless wearable and ongoing coaching. Neko Health takes a different route, with preventive examinations using its own scanners and clinicians. None has to wait for a longevity drug to make it through a clinical trial before it can earn revenue.

Oura announced six million paid members in October 2026. WHOOP said in July 2026 that it had passed three million members. Neko Health reported in August that more than 100,000 people in Sweden and the United Kingdom had received a scan, and that 75% of first-time customers booked and prepaid for another visit. Those are three ways of getting customers to pay repeatedly for health information.

Oura and WHOOP are also expanding into services tied more closely to medical care. The next test is whether those services bring enough value to justify customers keeping their subscriptions, alongside the steady launch of new devices.

Has Oura left WHOOP behind in the longevity wearable race?

No, the longevity wearable race is still close: Oura is valued at 1.1x WHOOP, and both are moving into broader healthcare services.

Oura's ring collects sleep, temperature and recovery data, with more tools for women's hormonal health. WHOOP pairs its wearable with coaching, and in August 2026 it opened clinician-reviewed Advanced Labs blood testing to customers without a wearable membership. That gives WHOOP a way to sell health services beyond its device audience.

Oura prepared a public offering in 2026 but postponed it in September, citing market conditions. According to Axios, the planned offering faced difficulty getting the price Oura wanted even though investors had subscribed for shares. Oura remained private, leaving its place in our ranking unchanged.

WHOOP has a strong athlete-focused brand. Oura has a larger paid membership. Their competition is increasingly about who can make daily health data useful enough for customers to keep paying, even when the excitement around a new device fades.

How many longevity startups are worth at least $1B?

Only 9 longevity startups in our ranking have valuations that make them confirmed unicorns, and 2 qualify as decacorns.

The unicorns span much more than anti-aging drugs. Oura and WHOOP exceed the higher threshold. Neko Health, Altos Labs, NewLimit, Function Health, Retro Biosciences, Eight Sleep and Midi Health also qualify because their entire valuation ranges reach the unicorn threshold. That puts wearables, scanning, laboratory testing, sleep technology and drug development in the same small group.

Cognito Therapeutics, valued at $700M to $1.3B, is a useful contrast: its range crosses the unicorn threshold, but the low end falls short. Cognito is testing a noninvasive device for Alzheimer's disease, a business with very different clinical requirements from a paid health wearable.

The rest of the longevity ranking sits far below the famous names. We place 137 companies in the below-$1B bracket, from preventive-health services to early-stage biotechnology. A handful of attention-grabbing valuations can make this industry look richer across the board than it is.

Are consumer products beating longevity drug startups on valuation?

Yes, the highest-valued longevity startups currently sell products that people can use, while aging-drug developers are still working toward clinical proof.

Oura, WHOOP and Neko Health each sell ways for customers to monitor or check their health. Oura and WHOOP can refine their subscriptions while selling devices, and Neko Health can add scanning clinics and build a repeat-visit business. Eight Sleep sells a sleep system that adjusts temperature through the night. Function Health offers regular laboratory testing and follow-up information. Each has customers before a new medicine is approved.

Aging-biology startups are further from the market, but their upside may be much greater if their treatments work. Altos Labs studies cellular reprogramming. NewLimit is developing RNA medicines designed to reset aging cells. Retro Biosciences is testing ways to improve cellular maintenance and renewal. In an October 2026 update, NewLimit described progress in manufacturing and large-animal studies while still preparing for trials in people. Retro Biosciences has already moved its autophagy drug RTR242 into Phase 1 testing.

So investors are paying for two different things: customers who keep coming back, and science that still has to work. The consumer companies need to keep their customers; the drug companies must demonstrate that their biology produces safe, useful treatments.

Why is Neko Health valued so highly among longevity startups?

Neko Health is valued at $7.0B to $8.2B because its longevity scanning business has attracted paying customers who return, even though opening clinics takes real work and money.

In August 2026, Neko Health reported more than 350,000 people on its global waiting list or registered for a scan. It also said 75% of customers booked and prepaid for another scan after their first appointment. A waiting list can shrink quickly, but an advance booking is a stronger sign that people want to use the service again.

Neko Health opened its first US clinic in New York in September 2026. Neko Health's own report that month covered health findings from more than 80,000 members in Sweden and the United Kingdom. Neko Health's repeat-customer model gives the company something to build on as it moves into new cities, although each site still needs equipment and clinicians.

There is a medical point worth keeping separate. Neko Health combines skin imaging, cardiovascular checks, blood tests and physician review. That makes it a different service from a whole-body MRI scan like Prenuvo's. Its September findings describe changes seen among returning members, without a randomized comparison group. We can see evidence of demand and follow-up care while leaving the question of cause open.

Can longevity drug developers catch the consumer leaders?

Not yet: the longevity drug companies still trail the best-priced consumer health startups, despite very large bets on therapies that target aging.

Altos Labs has an estimated valuation of $2.5B to $5.0B. NewLimit is valued at $3.1B, and Retro Biosciences at $1.8B. Their approaches range from cellular reprogramming to medicines aimed at the mechanisms of aging. Unlike a ring or blood-testing membership, a drug must clear years of safety and effectiveness testing before reaching patients.

The companies are at different stages. Retro Biosciences has taken RTR242 into Phase 1, while Life Biosciences has dosed patients in a trial of its epigenetic-restoration treatment. NewLimit reported manufacturing scale-up and animal studies in October 2026. Cambrian Biopharma has a clinical-stage AMPK drug program in its portfolio, including reported Phase 1b findings in 2026. A successful human result could change investors' assessment of one of these businesses quickly.

The valuations need reading carefully too. Altos Labs is valued from comparisons with other companies, whereas NewLimit's valuation follows the terms of an equity financing. The table below shows selected longevity drug developers and where each stands in our ranking.

Startup	Valuation	Focus	Overall valuation rank
Altos Labs	$2.5B–$5.0B	Reprogramming	4
NewLimit	$3.1B	Reprogramming	5
Retro Biosciences	$1.8B	Aging therapies	7
Life Biosciences	$533M–$1.0B	Reprogramming	13
Juvenescence	$500M–$750M	Aging drugs	14
Cambrian Biopharma	$358M	Aging therapies	25
Rubedo Life Sciences	$145M–$300M	Senescence	36
Gero	$113M–$213M	AI drug discovery	44

Are longevity medicines finally reaching human patients?

Actually, yes: longevity medicines are beginning to reach patients in early clinical trials, with Life Biosciences testing a reprogramming therapy for age-related eye disease.

Life Biosciences announced its first participant in June 2026. In October, the company reported that its ER-100 treatment had been well tolerated in the first three participants with glaucoma through an early safety check. Visual-field measurements improved at some points for two participants. The trial remains at a very early stage and is designed primarily to assess safety.

Retro Biosciences is testing RTR242, a drug designed to improve autophagy, the process cells use to recycle damaged material. The company is studying it first in relation to Alzheimer's disease. NewLimit, meanwhile, has been reporting progress on reprogramming treatments that are still in preclinical development. These programs offer different routes to treating damage associated with aging.

Drug regulators ask companies to prove a benefit against a specific disease, such as glaucoma or Alzheimer's, instead of approving a medicine simply for aging. That is why today's first trials focus on defined medical problems. Early trial results will focus first on whether patients can use these treatments safely.

Is Altos Labs really worth that much for a longevity startup?

Not clearly: Altos Labs has raised $3.0B for cell-rejuvenation research, but its longevity valuation of $2.5B to $5.0B still rests on estimates rather than an announced recent price.

Altos studies whether old cells can be restored to a healthier state without losing what makes them work. Its broad research effort uses cellular reprogramming, laboratory biology and computational tools. Altos has also appointed Joan Mannick to lead clinical development, moving closer to the practical work of turning research into treatments. A company pursuing several basic research questions may uncover treatments for many conditions, though the path to a product is harder to see than at a startup building one specific medicine.

The Altos Labs valuation is based on comparisons with other companies, not the amount agreed in a recent financing. NewLimit and Retro Biosciences provide a useful contrast: both have more clearly defined development programs, and Life Biosciences has already reached human testing.

Altos could eventually create medicines that treat several age-related diseases. For now, a named drug candidate entering trials would make it easier to compare Altos with the other biotechnology startups in our ranking.

Are longevity testing platforms worth more than physical clinics?

Not always: Function Health, a testing platform, is valued at $2.5B, above most longevity clinic businesses, but Neko Health's clinic-based model is valued at $7.0B to $8.2B.

Function Health sells testing memberships and software that helps members understand laboratory results. Prenuvo operates MRI screening services. Human Longevity and Fountain Life offer more hands-on precision healthcare, and Everlab combines testing with preventive-care subscriptions in Australia. All ask customers to pay for a clearer view of their health before serious problems appear.

Running a clinic adds staff, equipment and space costs, which makes expansion harder than simply adding a software subscriber. But Neko Health has built its own scanning technology and achieved strong repeat-booking figures. That creates a different experience from a testing platform that sends members to third-party laboratories. Function Health also acquired imaging company Ezra by late 2025, so the line between a testing platform and physical scans is getting less clear.

The price differences continue among smaller companies. Superpower sells a preventive-health membership, Q Bio combines imaging with digital models of patients, and Biograph offers premium diagnostics. The table below shows how these longevity testing and clinic businesses compare in our ranking.

Startup	Valuation	Model	Overall valuation rank
Function Health	$2.5B	Lab membership	6
Prenuvo	$650M–$950M	MRI screening	12
Superpower	$390M–$470M	Health membership	19
Everlab	$290M–$340M	Preventive care	28
Human Longevity	$160M–$260M	Precision care	37
Fountain Life	$150M–$240M	Medical centers	39
Q Bio	$145M–$230M	Full-body scans	41
Biograph	$90M–$180M	Diagnostics	47
Ahead Health	$40M–$67M	Screening clinics	72

Do longevity body scans prove that they improve people's health?

No, even as longevity body scans grow in popularity, there is still no conclusive evidence that routine screening helps healthy people live longer.

The American College of Radiology advises against recommending total-body MRI screening for people without symptoms or relevant risk factors because the evidence is insufficient. In July 2026, the Radiological Society of North America described both the growth of these scans and the risk of extra testing after an unexpected finding. A scan can find something treatable, but it can also lead to worry, unnecessary biopsies and medical bills.

The services themselves differ. Prenuvo offers MRI screening, while Neko Health combines several types of imaging, cardiovascular checks and blood tests. Function Health mainly sells access to laboratory markers. We need to judge what each test looks for, whether the result leads to a useful decision and how reliably it finds conditions that matter.

Neko Health reported improved cardiovascular markers among members who returned for scans in its September 2026 study. The company also explained that the people who chose to return were not a randomized control group. Those findings are interesting, especially for follow-up care, without settling whether routine scanning improves lifespan.

Is women's midlife care creating longevity unicorns?

Yes, longevity care for women in midlife already has a unicorn in Midi Health, valued at $1.0B.

Midi provides virtual care for menopause, perimenopause and related conditions. Its February 2026 funding announcement described plans to expand access through health systems and employer channels. These are patients seeking treatment for symptoms they have today, which gives Midi a clearer route to paying customers than an experimental treatment for ovarian aging.

Gameto is working on something more specialized. Its Fertilo technology uses stem-cell-derived ovarian support cells to help mature eggs in IVF care. Hone Health and Lifeforce focus on hormone care and broader health optimization. They all address aging-related needs, but Gameto's treatment has a very different clinical and regulatory path from Midi's virtual appointments.

Midi also faces scrutiny over how it describes the benefits of its care. In February 2026, the National Advertising Division said Midi Health had permanently withdrawn specific advertising claims about menopause symptom relief during a review. It did not decide whether those claims were true.

Are longevity startups worth far more than the equity they raised?

Several longevity startups are valued at far more than the equity they have raised, though the gap is much larger for some businesses than others.

WHOOP has the highest comparable valuation-to-equity-raised multiple in our ranking at 10.3x, and Molecular You has the lowest at 0.9x. Neko Health stands at 7.4x, Eight Sleep at 6.0x and NewLimit at 4.8x. These multiples compare valuation with equity raised, not with sales or profits. They say how much value investors place on the business relative to the money raised over time.

WHOOP has built a business around wearable subscriptions and is adding medical testing. NewLimit is still paying for drug research and clinical preparation. Molecular You offers predictive biomarker assessments in a competitive testing market. Investors have different reasons for giving these companies their prices, and a high multiple alone is no guarantee of a good return.

For this comparison, we use only valuations supported by stated or round-implied prices and companies with complete equity-funding totals. The table below shows selected longevity startups, with the highest multiples first.

Startup	Valuation	Valuation / raised
WHOOP	$10.1B	10.3x
Neko Health	$7.0B–$8.2B	7.4x
Eight Sleep	$1.5B	6.0x
Integrated Biosciences	$340M–$570M	5.3x
NewLimit	$3.1B	4.8x
Loyal	$667M–$1.2B	4.7x
Prenuvo	$650M–$950M	4.5x
Midi Health	$1.0B	4.0x
Molecular You	$8M	0.9x

Does the United States dominate the longevity startup ranking?

Yes, American startups dominate the longevity ranking by number, with 94 companies against 12 in the United Kingdom and 10 in Switzerland.

The United States is home to major aging-biology developers such as Altos Labs, NewLimit and Retro Biosciences, alongside medical services including Function Health and Midi Health. The United Kingdom has testing businesses and biotechnology developers, while Switzerland includes preventive clinics and companies working on new therapies.

However, Oura is Finnish, and Neko Health is Swedish. Finland has 1 ranked company, while Sweden has 3. A country with a smaller startup count can still produce a company near the top. The counts here tell us where startups are based, not the combined dollar value of their valuations.

The table below shows the countries with the most longevity startups in our ranking and a company from each.

Country	Startups	Example
United States	94	NewLimit
United Kingdom	12	Tenpoint Therapeutics
Switzerland	10	Centenara Labs
India	4	Cent Health
Canada	3	Molecular You
Sweden	3	Neko Health
Australia	2	Everlab
France	2	Lucis
Germany	2	Refoxy Pharmaceuticals
Singapore	2	Gero
United Arab Emirates	2	Longevium

Which longevity startups have gone public or been acquired?

Our longevity ranking also tracks 8 startups that have gone public or been acquired, including Insilico Medicine, BioAge Labs and Bioniq, in a separate list.

Insilico Medicine listed on the Hong Kong Stock Exchange in December 2025 and has a $2.76B public-market capitalization in our separate list. The company develops AI-driven medicines across several diseases while maintaining an explicit healthy-longevity research mission. BioAge Labs, Telomir Pharmaceuticals and Genflow Biosciences are also listed. Their market values now change as shares trade, unlike a private valuation established at an equity round.

Thymmune Therapeutics, Bioniq, Circulate Health and Tally Health appear in the acquired group. Buyers have paid for a range of assets, from longevity supplements to medical research and preventive-health platforms. Oura considered a public listing in 2026 but postponed it in September, so it still belongs in the main private-company ranking.

The table below shows the longevity companies we track separately after an IPO or acquisition.

Startup	Status	Value
Insilico Medicine	IPO	$2.76B
BioAge Labs	IPO	$266M
Thymmune Therapeutics	Acquired	$140M
Telomir Pharmaceuticals	IPO	$73M
Bioniq	Acquired	$55M
Circulate Health	Acquired	$15M–$50M
Tally Health	Acquired	$15M–$40M
Genflow Biosciences	IPO	$14M

What does the longevity valuation ranking tell us?

Oura is number one in our longevity valuation ranking at $11.0B, while the strongest prices today generally belong to companies selling health monitoring and prevention rather than drugs that target aging.

The top is small. Only 9 longevity startups meet the unicorn threshold with their entire valuation range, and 2 meet the decacorn threshold. Most of the startups we studied are worth far less, even though many are tackling serious medical problems.

What investors pay for depends on the company. Oura and WHOOP have large membership businesses, Neko Health has a scanning service with strong repeat bookings, and Function Health offers a continuing relationship through lab testing. Altos Labs, NewLimit and Retro Biosciences are valued for the possibility of future therapies whose clinical results remain uncertain.

Some of those therapies are starting to be tested in people. Life Biosciences has reported early data from a glaucoma trial, while other companies are still preparing human studies. Success in a well-run trial could change how investors value an aging-biology startup, but safety setbacks could change the picture just as quickly.

The prices also rest on different kinds of evidence. Private funding rounds provide a valuation at a particular moment; many smaller companies only have estimated ranges. Readers should look at the valuation type and confidence beside each company, especially when comparing a recent priced round with an older estimate.

For now, longevity has a more developed business in measuring health than in extending human lifespan with drugs. The next change could come from a medicine that works, preventive care with stronger clinical evidence or a public listing that gives investors a traded share price.